Withdrawal drug offers symptom relief to Crohn's disease sufferers
Crohn's disease treatment
A Penn State College of Medicine pilot study suggests a low dose of naltrexone, a drug used to ease symptoms of alcohol and drug addiction, may also bring relief to people with Crohn's disease, a chronic inflammatory disorder of the intestine that affects an estimated 500,000 Americans. The study results were released online this week in an early edition of the American Journal of Gastroenterology.
A team of researchers led by gastroenterologist Jill P. Smith, M.D., and Ian S. Zagon, Ph.D., Distinguished Professor of neural and behavioral sciences, at the College of Medicine and Penn State Milton S. Hershey Medical Center, received NIH funding last summer to initiate a phase 2 trial of low-dose naltrexone and Crohn's.
In the pilot study, patients with diagnosed Crohn's disease were treated with a low dose of naltrexone and monitored for improvement of symptoms for 12 weeks. Quality of life surveys were given every four weeks for 16 weeks. The results, published this week, show that 89 percent of participants showed an improvement with therapy, while 67 percent achieved remission of symptoms. The only side effect to treatment was sleep disturbance in some patients.
Typical treatment for Crohn's involves using steroids or corticosteroids, which suppress the immune system and can have other toxic side effects. Treatment is often time-intensive and expensive, as well.
"This is a novel approach to treating a common disease, and it's simple, it's safe, and it costs far less than current standards of treatment," Smith said. "We don't yet know the exact mechanisms involved in how it works, but we're working on that, as well."